Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Takes Equity Stake in Somalogic as Firms Extend Research Pact

NEW YORK (GenomeWeb) – Somalogic said today that Novartis has extended its multi-year research agreement covering the use of Somalogic's aptamer-based proteomics platform for drug development work.

Under the extended agreement, the two companies will continue efforts begun under an initial 2011 agreement to build a proprietary version of Somalogic's SomaScan proteomics assay and develop novel Somamer binding reagents for preclinical and clinical applications in Novartis's portfolio.

Novartis will also take an equity stake in Somalogic as part of the agreement.

"Our ongoing relationship with Novartis is a model for how we seek to develop strong scientific collaborations that drive new discoveries and build value for both parties," Somalogic CEO Byron Hewett said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.